Dental implant surface cleaning with hydrogen bubbles

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
02/01/2023		[X] Protocol		
Registration date	Overall study status Ongoing Condition category	Statistical analysis plan		
16/01/2023		Results		
Last Edited		[] Individual participant data		
06/10/2025	Oral Health	[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

Peri-implantitis is a condition that occurs in the tissues surrounding dental implants. It is characterized by inflammation of the connective tissue around the tissue and loss of the supporting bone. The objective of the treatment of peri-implantitis is to resolve the inflammation of the soft tissues and stop the additional loss of the supporting bone. Non-surgical treatment is not enough to stop the disease, and surgical treatment has shown greater effectiveness and in the longer term. Factors such as the implant surface decontamination method have a significant influence on the results of surgical treatment. Several implant surface decontamination methods have been proposed but none of them has been shown to be better than the others. Decontamination methods should not only effectively remove the attached biofilm (bacteria) and calculus (hardened plaque), but also avoid any significant negative changes at the implant surface in order to

perform the reconstructive surgery around the implant surface and promote the reosseointegration (bone ingrowth into the implant).

The aim of this study is to evaluate the clinical effectiveness of the new implant surface decontamination method Galvosurge® as adjunctive to titanium brush in the decontamination of implant surface and treatment of peri-implant bone defects comparing with titanium brush alone.

Who can participate?

Systemically healthy patients aged 18 years and over with advanced peri-implantitis at one or more implants

What does the study involve?

Surgery procedures will be performed 1 month after non-surgical periodontal treatment. Infected tissues will be removed and implant surface decontamination will be performed with either Galvosurge® or a control method (titanium brush). The bone defect will be filled and the flaps will be sutured to their previous position. Sutures will be removed 2 weeks after surgical therapy. Clinical examinations will be performed at 4, 12, 24 and 48 weeks after surgery. Maintenance therapy will be carried out at 12, 24 and 48 weeks after therapy.

What are the possible benefits and risks of participating? The benefit of participating is the treatment of the peri-implant pathology and improved implant prognosis. There is no additional risk of participating.

Where is the study run from? Clínica Ortiz-Vigón (Spain)

When is the study starting and how long is it expected to run for? September 2022 to December 2025

Who is funding the study? Arrow Development S.L. (Spain)

Who is the main contact? Dr Erik Regidor Correa erik@archealth.eu

Contact information

Type(s)

Principal investigator

Contact name

Dr Alberto Ortiz-Vigón

Contact details

Alameda Urquijo nº 2 - 7ª planta Bilbao Spain 48008 +34 944 15 89 02 erik@archealth.eu

Type(s)

Scientific

Contact name

Dr Erik Regidor Correa

ORCID ID

https://orcid.org/0000-0003-3338-6379

Contact details

Alameda Urquijo nº 2 - 7ª planta Bilbao Spain 48008 +34 662025988 erik@archealth.eu

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Influence of new implant surface decontamination method (Galvosurge®) in the surgical reconstructive treatment of peri-implant related intrabony defects

Study objectives

Current study objectives:

The Galvosurge implant surface decontamination method as adjunctive method to titanium brush has a better outcome in terms of the effective removal of the attached biofilm and calculus from the implant surface when compared with the titanium brush method alone.

Previous study objectives:

The Galvosurge implant surface decontamination method has a better outcome in terms of the effective removal of the attached biofilm and calculus from the implant surface when compared with the titanium brush method.

Ethics approval required

Old ethics approval format

Ethics approval(s)

- 1. Approved 20/12/2022, Comité De Ética De La Investigación Con Medicamentos De Euskadi (CEIm-E; Postal address: C/ Donostia-San Sebastián, nº 1. Vitoria-Gasteiz 01010, Spain; +34 (0)945 015 634; ceic.eeaa@euskadi.eus), ref: PS2022077
- 2. Approved 27/12/2022, local ethics committee of Basque Country (BioCruces, Plaza del Hospital s/n, 48903 Barakaldo, Bilbao (Bizkaia), Bilbao, 48903, Spain; +34 (0)945 01 80 00; ceic. eeaa@euskadi.eus), ref: PS2022077

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Removal of the attached biofilm and calculus from dental implant surface

Interventions

Current interventions as of 06/10/2025:

Surgical procedures will be performed one month after non-surgical periodontal treatment. On the same day of surgical therapy an antibiotic will be administered for 7 days (amoxicillin 500 mg /7 days/8 hours). Full thickness flap will be elevated and infected tissues will be removed.

Implant surface decontamination will be performed with test (Titanium brush + Galvosurge®) or control methods (titanium brush) randomly assigned. Randomization will be performed using a Microsoft Excel®-generated randomization list, with the treatment allocation contained in sealed envelopes that will be prepared by a research assistant not involved as clinician or examiner. Both the patient and the clinician performing the surgical intervention will be masked to the group allocation until the randomization envelope will be opened intra-surgically. The examiner will be masked to the group allocation at all follow-up visits, and the patients will be asked not to reveal their treatment assignment to the examiners.

The intrabony defect will be filled with Xenogain Collagen® and Xenoprotect® resorbable membrane and the flaps will be sutured to their previous position. Sutures will be removed 2 weeks after surgical therapy. Clinical examinations will be performed at 4, 12, 24 and 48 weeks after surgical therapy. Maintenance therapy will be realized at 12, 24 and 48 weeks after therapy.

Previous interventions:

Surgical procedures will be performed one month after non-surgical periodontal treatment. On the same day of surgical therapy an antibiotic will be administered for 7 days (amoxicillin 500mg /7 days/8 hours). Full thickness flap will be elevated and infected tissues will be removed.

Implant surface decontamination will be performed with test (Galvosurge®) or control methods (titanium brush) randomly assigned. Randomization will be performed using a Microsoft Excel®-generated randomization list, with the treatment allocation contained in sealed envelopes that will be prepared by a research assistant not involved as clinician or examiner. Both the patient and the clinician performing the surgical intervention will be masked to the group allocation until the randomization envelope will be opened intra-surgically. The examiner will be masked to the group allocation at all follow-up visits, and the patients will be asked not to reveal their treatment assignment to the examiners.

The intrabony defect will be filled with Xenogain Collagen® and Xenoprotect® resorbable membrane and the flaps will be sutured to their previous position. Sutures will be removed 2 weeks after surgical therapy. Clinical examinations will be performed at 4, 12, 24 and 48 weeks after surgical therapy. Maintenance therapy will be realized at 12, 24 and 48 weeks after therapy.

Intervention Type

Procedure/Surgery

Primary outcome(s)

A composite definition of successful treatment outcome defined as the absence of bleeding or suppuration on probing, absence of peri-implant probing depth ≤5 mm and mucosal recession ≤1 mm at 4, 12, 24 and 48 weeks. One calibrated examiner will perform the assessments. The following variables will be assessed at four sites around the implant: Plaque, probing pocket depth (PPD), bleeding on probing (BoP), probing attachment level (PAL) recession (REC). Keratinized mucosa (KM) will be measured in the buccal aspect of each included implant

Key secondary outcome(s))

Measured at 4, 12, 24 and 48 weeks:

- 1. Radiographic filling of the defect will be measured with Image J Software
- 2. Risk of appearance of complications measured with a questionnaire recording suppuration, membrane exposure or grafting material exposure and soft tissue dehiscence.
- 3. Patient-reported outcomes measurements: patient pain perception and general satisfaction with surgical procedure and final outcomes.
- 4. Need for analgesia after surgery measured using patient records
- 5. Intervention time measured using patient records
- 6. Soft and hard tissue volumetric changes measured with an intraoral scanner and compared with implant planning software
- 7. Impact of defect configuration in treatment outcomes; taking into account the presence or absence of buccal bony wall and the number of bony walls the researchers will perform a further analysis of the impact of these defects in the final reconstructive outcomes

Completion date

01/12/2025

Eligibility

Key inclusion criteria

- 1. Age ≥ 18 years
- 2. Peri-implant bone defect ≥3 mm assessed radiographically
- 3. Peri-implant pocket depth (PPD) ≥5 mm combined with bleeding on probing or suppuration
- 4. Intra-surgically, bone defect must have at least an intraosseous component of 3 mm and a width of no more than 4mm
- 5. Implants ≥1 year in function

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

40

Key exclusion criteria

- 1. Treated for peri-implantitis during the previous 6 months
- 2. Intake of systemic or local antibiotics during the previous 6 months

- 3. Pregnant patients
- 4. Systemically unhealthy patients
- 5. Patients allergic to collagen

Date of first enrolment

01/02/2023

Date of final enrolment

01/09/2024

Locations

Countries of recruitment

Spain

Study participating centre

Clínica Ortiz-Vigón

Alameda Urquijo nº 2 - 7ª planta

Bilbao

Spain

48008

Sponsor information

Organisation

Arrow Development S.L.

Funder(s)

Funder type

Industry

Funder Name

Arrow Development S.L.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication

IPD sharing plan summaryPublished as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<u>Protocol file</u>			04/01/2023	No	No
Protocol file	version 2		06/10/2025	No	No